Gilead's (GILD) Kite Announces Positive Data on Yescarta
Zacks Investment Research | Jun 29, 2021 07:08AM ET
Gilead Sciences’ GILD Kite announced positive top-line results from the primary analysis of the global phase III multicenter study, ZUMA-7.
ZUMA-7 evaluated a one-time infusion of the CAR T-cell therapy Yescarta compared to the standard of care (SOC) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL).
Results showed the superiority of Yescarta over the SOC in the targeted patient population. Yescarta improved event-free survival by 60% over chemotherapy plus stem cell transplant in second-line relapsed or refractory LBCL.
With a median follow-up of two years, the study met the primary endpoint of event-free survival. The study also met the key secondary endpoint of objective response rate (ORR). The interim analysis of overall survival (OS) showed a trend favoring Yescarta but this data is immature at this time, and further analyses are planned for the future.
Yescarta is a CD19-directed, genetically modified autologous T cell immunotherapy, indicated for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL). It is also approved for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,
Please note that ZUMA-7 was conducted under a Special Protocol Agreement (SPA) with the FDA, whereby the trial design, clinical endpoints and statistical analysis were agreed on, in advance, with the agency.
Based on the positive results of this study, Kite plans to initiate discussions with the FDA, the European Medicines Agency and other global health authorities regarding the submission of a supplemental biologics license application later this year for a potential label expansion of Yescarta.
Gilead acquired Kite Pharma to foray into the emerging field of cell therapy. Gilead’s CAR T cell therapy franchise comprises Yescarta and Tecartus. Tecartus is approved for the treatment of relapsed or refractory mantle cell lymphoma. Both drugs are gaining traction and have bolstered the cell therapy product franchise for the company.
Gilead’s stock has gained 16.6% in the year so far compared with the industry 's growth of 1%.
Get The News You Want
The massive decline in sales of its HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues. The approval of other indications for these therapies will boost the franchise’s performance. However, competition is stiff from the likes of Novartis’ ALLO .
Concurrently, Gilead completed the submission of a new drug application (NDA) to the FDA seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection. The company plans to submit marketing authorization applications for lenacapavir to the European Medicines Agency and other global agencies in the coming months.
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
h3 +1,500% Growth: One of 2021’s Most Exciting Investment Opportunities/h3In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.